Publications en collaboration avec des chercheurs de Hospital Vall d'Hebron (151)

2024

  1. A projected cost-utility analysis of avacopan for the treatment of antineutrophil cytoplasmic antibody-associated vasculitis in Spain

    Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 24, Núm. 2, pp. 227-235

  2. Association between occupational exposure and chronic obstructive pulmonary disease and respiratory symptoms in the Spanish population

    Archivos de Bronconeumologia, Vol. 60, Núm. 1, pp. 16-22

  3. Consensus statement of the Spanish Society of Neurology on the treatment of multiple sclerosis and holistic patient management in 2023

    Neurologia, Vol. 39, Núm. 2, pp. 196-208

  4. Efficacy and safety of cemiplimab in the treatment of advanced cutaneous squamous cell carcinoma: A multicentre real-world retrospective study from Spain and systematic review of the published data

    Journal of the European Academy of Dermatology and Venereology

  5. Integrating AIPSS-MF and molecular predictors: A comparative analysis of prognostic models for myelofibrosis

    HemaSphere

  6. Renal Disease in Metabolic Syndrome: the Hidden Role of Intrarenal Ischemia

    Kidney International Reports

  7. The prognostic impact of non-driver gene mutations and variant allele frequency in primary myelofibrosis

    American Journal of Hematology

  8. [Translated article] Requirements for Accessing New Dermatology Drugs in Spain: Results of the EQUIDAD Study

    Actas Dermo-Sifiliograficas, Vol. 115, Núm. 3, pp. T237-T245

2023

  1. Budesonide as first-line treatment in patients with autoimmune hepatitis seems inferior to standard predniso(lo)ne administration

    Hepatology, Vol. 77, Núm. 4, pp. 1095-1105

  2. Cost of Treating Cutaneous T-Cell Lymphoma in Spain: Analysis of MICADOS Study Data by Disease Stage

    Actas Dermo-Sifiliograficas

  3. Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance-Like Phenotype in Patients With Monoclonal Gammopathies

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 16, pp. 3019-3031

  4. Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin

    Nature Communications, Vol. 14, Núm. 1

  5. Hepatic encephalopathy is not a contraindication to pre-emptive TIPS in high-risk patients with cirrhosis with variceal bleeding

    Gut, Vol. 72, Núm. 4, pp. 749-758

  6. Juvenile idiopathic arthritis in the young adult. Methodology, objectives, and initial data from the JUVENSER registry

    Reumatologia Clinica, Vol. 19, Núm. 6, pp. 328-333

  7. Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance

    Nature Communications, Vol. 14, Núm. 1

  8. Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis

    HemaSphere, Vol. 7, Núm. 1, pp. E818

  9. Measured GFR in murine animal models: review on methods, techniques, and procedures

    Pflugers Archiv European Journal of Physiology, Vol. 475, Núm. 11, pp. 1241-1250

  10. PHYOX2: a pivotal randomized study of nedosiran in primary hyperoxaluria type 1 or 2

    Kidney International, Vol. 103, Núm. 1, pp. 207-217

  11. Philadelphia-negative chronic myeloproliferative neoplasm follow-up: when the phone rings. Changes during the COVID-19 pandemic and patient satisfaction. Experience in 30 health centers in Spain

    Annals of Hematology, Vol. 102, Núm. 2, pp. 447-456

  12. Post-transplant diabetes mellitus and renal cell cancer after renal transplantation

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, Vol. 38, Núm. 6, pp. 1552-1559